suitable for the diagnosis of MPD including those with as little as 1% mutant; the JAK2 V617F burden thus measured is lower than in purified granulocytes and may be adjusted using the % neutrophils. For the follow-up of the mutated clone in treated patients, however, it is advisable to assess JAK2 V617F before and during treatment in the same population of purified cells as blood cell ratios are altered and the variation of the JAK2 V617F burden measured in whole blood increases and no longer correlates with blood parameters. For the purpose of assessing the JAK2 V617F burden during treatment, blood granulocytes remain the easiest cells to obtain and purify. CD95 (Fas/Apo-1) and TNF-related-apoptosis-inducing-ligand (TRAIL/Apo-2) are two of the six cellular receptors belonging to the TNF superfamily regulating the extrinsic apoptotic pathways after the interaction with their cognate ligand. Both CD95 and TRAIL are potential candidates to target apoptosis in malignant cells, even if their simple expression is not an essential feature for apoptosis sensitivity. 1 In preclinical studies, the administration of soluble recombinant TRAIL (rTRAIL) or anti-CD95 agonistic antibody in experimental animals induced significant tumor regression without systemic toxicity. 2, 3 This approach can be used to overcome chemotherapy resistance, for example, several types of leukemias; in this case, tumor resistance can be bypassed by a combined therapy including the activation of death receptors (DR; extrinsic pathway) and chemotherapy (intrinsic way). 1 In this contest, a plethora of naturally occurring molecules with potential chemopreventive properties have been recently described. 4 Among these, quercetin (3,3 0 ,4 0 ,5,7-pentahydroxyflavone), the major dietary flavonoid, abundantly present in a broad range of fruits and vegetables, has been intensively studied for its antioxidant, antiinflammatory, antiproliferative and, more recently, apoptotic effects in cell cultures and animal models. 5 We have previously shown that quercetin, at 50 mM concentration, sensitized HPB-ALL cells to CD95-mediated apoptosis. 6, 7 The same cell line was strongly resistant to TRAIL treatment (up to 50 ng/ml), both in terms of caspase 3 activation and cell viability (Table 1 ). This observation confirmed the unusual resistance of HPB-ALL cells, similarly to acute lymphoblastic leukemias, to DR-mediated apoptotic stimuli. Quercetin was able to bypass this resistance only in the presence of a functional CD95 receptor; 6 in fact, the enhancement effect of anti-CD95 and quercetin was confirmed by poly(ADP-ribose) polymerase (PARP) degradation. The immunoblot reported in Figure 1a shows the degradation of PARP (120 kDa) by caspase 3 with the appearance of the 85-kDa inactive fragment. On the opposite, quercetin was incapable of sensitizing HPB-ALL cells to rTRAIL induction, although TRAIL-R2 was clearly detectable by immunoblotting (data not shown), suggesting the possible expression of an inactive form of the receptor.
Jurkat cell line was reported to be very responsive to both TRAIL and anti-CD95 inducers, and similarly to HPB-ALL, Jurkat cells are sensitive to the enhancement activity of anti-CD95 and quercetin. When quercetin was associated with anti-CD95 or rTRAIL, caspase 3 activity increased 3-and 2.5-fold, respectively, compared to the treatment with DRs alone (Table 1 ). The enhancing effect of TRAIL and quercetin on Jurkat cells was also confirmed by cell viability (Table 1) and PARP degradation ( Figure 1b ). These results demonstrate that quercetin enhanced DR-dependent apoptosis in Jurkat cells, a lymphoid cell line partially sensitive to CD95 and TRAIL induction.
To confirm the large spectrum of activity of quercetin in enhancing DR-mediated apoptosis observed in the two lymphoid cell lines described above, we measured its effect on K-562 and U-937, two myeloid cell lines, chosen for their different sensitivities to death ligands and for their ability to differentiate in vitro. Table 1 shows that K-562 cells were resistant to anti-CD95-mediated apoptosis also at an antibody concentration four-fold higher than in other cell types, neither quercetin was able to sensitize them, suggesting absence or loss of function of CD95 receptor. K-562 cells were also resistant to rTRAIL-induced cell death in terms of cell viability and caspase 3 (Table 1) ; however, when quercetin was associated with rTRAIL, caspase 3 increased eight-fold when compared to the treatment with rTRAIL alone (Table 1 ). This strong change in caspase 3 activity resulted in increased PARP degradation ( Figure 1c ) and in a parallel loss of cell viability (60% decrease; Table 1 ). Similarly, U-937 cells were resistant to both anti-CD95 and rTRAIL-mediated apoptosis; however, when quercetin was associated to both treatments, an enhancement apoptotic effect was measured. In fact, caspase 3 activity increased four-and three-fold, respectively, when compared with anti-CD95 or rTRAIL alone (Table 1 ). In parallel, PARP degradation was clearly measured (Figure 1d) , and cell viability decreased 50 and 40% after coincubation of quercetin with rTRAIL or anti-CD95, respectively (Table 1) .
These data indicated that quercetin enhances CD95-mediated apoptosis in HPB-ALL, Jurkat and U-937 cells. In addition, the molecule exerts a similar activity on TRAIL-mediated apoptosis in Jurkat, U-937 and K-562 cells (Table 1 and Figure 1) . Therefore, we conclude that the enhancement activity of quercetin in inducing apoptosis, when associated to DRs, must not be seen as a peculiar mechanism of a single cell line, but as a common feature of apoptotic-resistant cells. As changes in caspase 8 activity after quercetin and DR treatment strictly paralleled those of caspase 3 (data not reported), we hypothesize that quercetin triggers inhibitor(s) located above caspase 8 and shared by both TRAIL and CD95 pathways. In such a way, quercetin removes or reduces the resistance to either death ligands. We can predict that quercetin will enhance apoptosis in malignant cell lines possessing a structurally functional CD95 or TRAIL receptor, but with a total or partially impaired downstream pathway.
Previously, we have shown that flavonoids structurally similar to quercetin were not able to mimic quercetin effects, at least in HPB-ALL cells. 6 Similarly, resveratrol, a polyphenol with very promising chemopreventive potential, 4 did not show any enhancing or additive effects on K-562 treated with TRAIL (data not shown). As resveratrol behaves as a differentiating agent on K-562, 8 we asked if (i) the differentiating process was able to interfere with quercetin activity on death ligands; and (ii) differentiated cells were equally responsive to the enhancement effect of quercetin and death ligands. As shown in Table 1 , in K-562 cells treated for 24 h with 50 mM resveratrol, caspase 3 activity remained low after treatment with rTRAIL, and a fourfold decrease was measured when quercetin was coincubated with rTRAIL (compare (c) with (c 0 ) in Table 1 ). We concluded that in differentiated K-562, the enhancing apoptogenic effect of quercetin was impaired. This phenomenon was not limited to K-562. Other differentiated cell lines, such as HPB-ALL and U-937 (Table 1) , were equally resistant to the association between quercetin and death ligands. In HPB-ALL, 200 nM PMA (phorbol esther 12-O-tetradecanoylphorbol-13-acetate) for 24 h induced differentiation, as measured by slow growth rate and expression of mature T-lymphocyte surface antigens (M Russo, C Gianfrani and GL Russo, unpublished). When differentiated HPB-ALL cells were treated with anti-CD95, caspase 3 activity was lowered by about six-fold, respect to undifferentiated cells (compare (a) with (a') in Table 1 ). Moreover, the combination of quercetin Cell viability was calculated by neutral red assay 7 as percent of vital cells7s.e. compared to controls after 16-24 h stimulation with rTRAIL (superkiller TRAIL, Alexis-Vinci-Biochem, Vinci, Italy) and anti-CD95 (clone CH11, Immunotech, Marseille, France) at the indicated concentrations. Caspase-3 activity (nmol AFC/min/mg protein) is reported as -fold increase compared to untreated cells7s.e. after 6 h stimulation. ND, not determined. Letters in paranthesis are referred to description in the text.
Letters to the Editor and anti-CD95 in differentiated cells resulted in an eight-fold reduction in caspase 3 activity when compared to proliferating HPB-ALL cells (compare (b) with (b') in Table 1 ). PMA induced morphological and biochemical changes also in hystiocytic human lymphoma cell line U-937 stimulating cell adhesion and leading to a mature monocyte-like phenotype. Similar to HPB-ALL and K-562 cell lines, differentiated U-937 developed a marked resistance to rTRAIL (four-fold decrease) and anti-CD95 (two-fold decrease) in terms of caspase 3 activation (compare (d) with (d') and (e) with (e') in Table 1 ). As a consequence, resistance of differentiated U-937 cells was stronger when quercetin was associated to rTRAIL (12-fold decrease; (f) vs (f 0 ) in Table 1 ) and anti-CD95 (six-fold decrease; (g) vs (g 0 ) in Table 1 ). Finally, human peripheral leukocytes, freshly isolated from healthy donors and employed as a model of normal cells, were insensitive to all treatments described above (data not shown).
Data presented clearly indicate that the enhancing effects of quercetin associated to TRAIL and CD95 in inducing apoptosis are strongly detectable in actively proliferating cells, but lose their efficacy in resting or differentiated cells. We conclude that, independent from the differentiating agents (resveratrol vs PMA) and cell lines employed, quercetin enhances DR-mediated apoptosis exclusively in rapidly growing malignant cell lines, whereas it is ineffective on their differentiated counterparts.
Quercetin concentration used in the present study (25-50 mM) ensured low toxicity and an effective uptake of the molecule. In different cellular model, such as HL60 cell line and blast cells isolated from leukemic patients, we applied a quercetin concentration ranging between 5 and 10 mM, without losing the effects of the molecule in inducing DR-mediated apoptosis (data in progress). Bioavailability studies suggest a rapid uptake and transformation of the molecule. Therefore, we suppose that quercetin accumulates and is active into the cells at concentration much lower than those applied to the cell culture medium. It is worthwhile to note that quercetin concentrations of 25-50 mM, used in this study, are compatible with a daily dietary intake of the molecule in European Countries of 25-30 mg, a dose neither toxic nor carcinogenic in animal models, where some renal and/or liver toxicity was observed at doses above 1900 mg/kg/day. 5 In humans, quercetin supplementation (20-500 mg/day) resulted in a serum concentration ranging between 1 and 5 mM aglycone equivalents at the highest dose. 9 Finally, a quercetin dose of 25 mg/kg body weight significantly reduced the DMBA-induced tumor volume in rats. 10 A more in-depth studies on quercetin bioavailability should facilitate correlation between in vitro with in vivo studies, increase our understanding of dose-response relationships and facilitate extrapolation of results from in vitro to animal models and finally in humans.
Our model suggests that in apoptosis-resistant cells expressing a functional DR (CD95 and/or TRAIL), quercetin acts on molecule(s) common to both pathways and possibly located at DISC level, where the two pathways converge. Potential quercetin target(s) might be not expressed and/or activated in normal and differentiated cells.
Specific target in cancer treatment is a desirable objective in pharmacological research, but actual chemotherapy and/or radiotherapy is still far from reaching this goal. Since TRAIL represents a new potential anticancer drug direct against apoptotic-resistant cancers, including leukemias, 11 our study opens new applicative perspectives supported by the observation that quercetin and rTRAIL are effective exclusively toward transformed cell line, without toxicity on differentiated cells. A combined therapy including quercetin and TRAIL might be more effective in inducing cell death in TRAIL responsive tumors. Preliminary data obtained ex vivo on leukemia blasts from patients affected by myeloid or lymphoid leukemia support this hypothesis. Table 1 . CD, T, Q and UN indicate anti-CD95, rTRAIL, quercetin and untreated cells, respectively. Anti-PARP monoclonal antibody was from Santa Cruz Biotechnology (Heidelberg, Germany). Arrow indicates the 85 kDa cleaved PARP fragment. Images are representative of one experiment out of three performed for each cell line employed in this study.
